GC Cell Corporation (KOSDAQ:144510)

Market Cap	361.40B
Revenue (ttm)	184.36B
Net Income (ttm)	-3.39B
Shares Out	15.03M
EPS (ttm)	-225.52
PE Ratio	n/a
Forward PE	n/a
Dividend	100.00 (0.42%)
Ex-Dividend Date	n/a

Volume	259,722
Average Volume	57,003
Open	24,650
Previous Close	23,800
Day's Range	23,950 - 25,100
52-Week Range	21,050 - 47,950
Beta	0.85
RSI	59.87
Earnings Date	Feb 7, 2025

About GC Cell

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 752
• Stock Exchange: KOSDAQ
• Ticker Symbol: 144510